MX2017009723A - Uso de prg4 como agente antiinflamatorio. - Google Patents

Uso de prg4 como agente antiinflamatorio.

Info

Publication number
MX2017009723A
MX2017009723A MX2017009723A MX2017009723A MX2017009723A MX 2017009723 A MX2017009723 A MX 2017009723A MX 2017009723 A MX2017009723 A MX 2017009723A MX 2017009723 A MX2017009723 A MX 2017009723A MX 2017009723 A MX2017009723 A MX 2017009723A
Authority
MX
Mexico
Prior art keywords
prg4
inflammatory
inflammatory agent
pro
lubricin
Prior art date
Application number
MX2017009723A
Other languages
English (en)
Inventor
D Jay Gregory
d sullivan Benjamin
Avery Schmidt Tannin
Elsaid Khaled
R Truitt Edward
Krawetz Roman
Szmydynger-Chodobska Joanna
Fareed Jawed
Chodobski Adam
Original Assignee
Lubris Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc filed Critical Lubris Llc
Publication of MX2017009723A publication Critical patent/MX2017009723A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

En el presente documento se divulgan métodos de uso de glicoproteína PRG4, también conocida como lubricina, para reducir, inhibir o regular a la baja las vías proinflamatorias en pacientes con riesgo de sufrir o que sufren de una respuesta inflamatoria o síntoma de alergia a través de la antagonización de CD44, la regulación de la producción de citoquinas proinflamatorias, la inhibición de la translocación de NF-kB y/o facilitando la eliminación de alérgenos o restos de la matriz o restos celulares inductores de inflamación.
MX2017009723A 2015-01-26 2016-01-26 Uso de prg4 como agente antiinflamatorio. MX2017009723A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107799P 2015-01-26 2015-01-26
US201562273059P 2015-12-30 2015-12-30
PCT/US2016/014952 WO2016123123A1 (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
MX2017009723A true MX2017009723A (es) 2018-08-15

Family

ID=55361962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009723A MX2017009723A (es) 2015-01-26 2016-01-26 Uso de prg4 como agente antiinflamatorio.

Country Status (21)

Country Link
US (2) US10967048B2 (es)
EP (2) EP3718559A1 (es)
JP (2) JP6758299B2 (es)
KR (1) KR20170123619A (es)
CN (2) CN113908257A (es)
AU (2) AU2016211694B2 (es)
BR (1) BR112017015310A8 (es)
CA (1) CA2972817A1 (es)
CL (2) CL2017001893A1 (es)
EA (1) EA036291B1 (es)
ES (1) ES2808199T3 (es)
HK (1) HK1247834A1 (es)
IL (2) IL253596B (es)
MA (1) MA53108A (es)
MX (1) MX2017009723A (es)
PH (1) PH12017501323A1 (es)
RU (1) RU2017129880A (es)
SG (2) SG10201809947UA (es)
TN (1) TN2017000270A1 (es)
WO (1) WO2016123123A1 (es)
ZA (1) ZA201705378B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
AU2014354859B2 (en) 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
US11089832B2 (en) 2015-05-01 2021-08-17 Gentex Corporation Helmet impact attenuation article
PT3300482T (pt) 2015-05-19 2021-10-15 Lubris Llc Uso de prg4 para melhorar a acuidade visual dinâmica e as aberrações de ordem superior
CN106215170A (zh) * 2016-08-23 2016-12-14 重庆医科大学 白细胞介素36α在制备治疗、诊断或预防脓毒症药物中的用途
WO2018217919A1 (en) 2017-05-23 2018-11-29 Harmony Development Group, Inc. Tethered implantable device having an apical base plate with a hydraulic intracardiac adjusting mechanism
WO2019006152A1 (en) 2017-06-28 2019-01-03 Harmony Development Group, Inc. INFLATABLE TRANSDUCTION IMPLANT SYSTEM COMPRISING AN ANNULAR DOUBLE FORCE TRANSDUCTION IMPLANT
WO2019173385A1 (en) 2018-03-05 2019-09-12 Harmony Development Group, Inc. A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
EP3810181A4 (en) * 2018-06-21 2022-03-30 Lubris LLC LUBRICINE FOR WOUND HEALING
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
CN109620952A (zh) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
WO2020232148A1 (en) * 2019-05-13 2020-11-19 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
US20220332839A1 (en) * 2019-06-03 2022-10-20 Lubris Llc Use of prg4 to treat cancer
US20230256052A1 (en) * 2020-07-07 2023-08-17 University Of Connecticut Method and composition for reducing or preventing bone resorption
IT202000022636A1 (it) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN114184792B (zh) * 2021-11-17 2024-05-28 中国人民解放军总医院第二医学中心 冠心病标志物il-29及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
AU2001251342A1 (en) 2000-04-05 2001-10-23 Archer-Daniels-Midland Company Ketogulonigenium endogenous plasmids
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
DK1663291T3 (da) * 2003-08-14 2012-07-02 Wyeth Llc Rekombinante lubricinmolekyler og anvendelser deraf
US20090155200A1 (en) 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
AU2005267012A1 (en) * 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
EP1827478A4 (en) 2004-12-03 2009-08-05 Mucosal Therapeutics Llc METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
CN101077887A (zh) * 2006-05-23 2007-11-28 中国医学科学院血液学研究所 人促造血细胞增殖的细胞因子及其制备方法和用途
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US20090191287A1 (en) 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
SI2285364T1 (sl) 2008-05-07 2015-03-31 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
WO2010083239A2 (en) * 2009-01-13 2010-07-22 Truitt Edward R Iii Therapeutic modulation of vaginal epithelium boundary lubrication
CA2762989C (en) 2009-05-22 2021-04-13 Benjamin Sullivan Prg4 for treatment of oral cavity boundary lubrication disorders
ES2634505T3 (es) 2009-08-13 2017-09-28 Lubris Llc Tratamiento de PRG4 para la cistitis intersticial
WO2011091000A2 (en) 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
PL2948553T3 (pl) * 2013-01-25 2020-11-16 Baylor College Of Medicine Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
AU2014354859B2 (en) 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
ES2808199T3 (es) 2015-01-26 2021-02-25 Lubris Llc Uso de PRG4 como un agente antiinflamatorio
PT3300482T (pt) 2015-05-19 2021-10-15 Lubris Llc Uso de prg4 para melhorar a acuidade visual dinâmica e as aberrações de ordem superior
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
RU2017129880A (ru) 2019-03-04
EA201791688A1 (ru) 2018-01-31
JP2020189878A (ja) 2020-11-26
AU2016211694A1 (en) 2017-08-31
CN107847556A (zh) 2018-03-27
HK1247834A1 (zh) 2018-10-05
CA2972817A1 (en) 2016-08-04
EP3250221A1 (en) 2017-12-06
EA036291B1 (ru) 2020-10-22
ZA201705378B (en) 2020-11-25
PH12017501323A1 (en) 2018-02-05
WO2016123123A1 (en) 2016-08-04
EP3718559A1 (en) 2020-10-07
EA201791688A8 (ru) 2018-05-31
AU2022200812A1 (en) 2022-02-24
IL253596A0 (en) 2017-09-28
ES2808199T3 (es) 2021-02-25
CL2018003302A1 (es) 2019-01-04
US11717557B2 (en) 2023-08-08
SG11201705636SA (en) 2017-08-30
JP2018505867A (ja) 2018-03-01
IL253596B (en) 2021-08-31
BR112017015310A2 (pt) 2018-01-16
MA53108A (fr) 2021-05-12
RU2017129880A3 (es) 2019-08-22
AU2016211694B2 (en) 2021-11-11
CN107847556B (zh) 2021-09-24
CN113908257A (zh) 2022-01-11
BR112017015310A8 (pt) 2021-02-23
US20180015141A1 (en) 2018-01-18
US20210299214A1 (en) 2021-09-30
SG10201809947UA (en) 2018-12-28
JP6758299B2 (ja) 2020-09-23
JP7212653B2 (ja) 2023-01-25
EP3250221B1 (en) 2020-05-27
IL285553A (en) 2021-09-30
US10967048B2 (en) 2021-04-06
CL2017001893A1 (es) 2018-06-15
TN2017000270A1 (en) 2018-10-19
KR20170123619A (ko) 2017-11-08

Similar Documents

Publication Publication Date Title
PH12017501323A1 (en) Use of prg4 as an anti-inflammatory agent
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EP4275705A3 (en) Pancreatitis treatment
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MY171929A (en) Corticosteroids for the treatment of joint pain
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
WO2014115167A3 (en) Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
WO2014151456A3 (en) Treatment of inflammatory diseases
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2015013703A (es) Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
IL286268A (en) Pridopidine for the treatment of mitochondrial diseases and disorders and symptoms associated with these diseases
TN2017000109A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX2019000677A (es) Células miméticas de células b.
JP2016513650A5 (es)
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases